Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shaanxi Micot Technology
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Ischemic Stroke|Reperfusion Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MT200605-I-C01 | P1 |
Completed |
Ischemic Stroke |
2024-01-22 |
|
CTR20231741 | P1 |
Not yet recruiting |
Ischemic Stroke|Reperfusion Injury |
None |